Levetiracetam
Product Images NDC 17856-0685

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 17856-0685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corps, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

690afec4-figure-01 (Levetiracetam Oral Solution 1)

Chemical structure of Levetiracetam, showing its molecular arrangement including a pyrrolidone ring attached to an ethyl group and an amide functional group.*

FDA Label Image

690afec4-figure-02 (Levetiracetam Oral Solution 2)

Bar chart comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The chart shows higher percentages for Levetiracetam groups compared to placebo, with percentages labeled above each bar.*

FDA Label Image

690afec4-figure-03 (Levetiracetam Oral Solution 3)

Bar graph comparing the percentage of patients with a specified outcome across three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The y-axis shows the percentage of patients from 0% to 45%.*

FDA Label Image

690afec4-figure-04 (Levetiracetam Oral Solution 4)

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The Placebo group shows approximately 14.4% of patients while the Levetiracetam group shows about 39.4%. The y-axis is labeled '% of Patients' with values from 0% to 45%.*

FDA Label Image

690afec4-figure-05 (Levetiracetam Oral Solution 5)

A bar chart comparing the percentage of patients between placebo (N=97) and Levetiracetam (N=101) groups. The placebo group shows 19.6% of patients, while the Levetiracetam group shows 44.6%, indicating a higher percentage in the Levetiracetam group.*

FDA Label Image

690afec4-figure-06 (Levetiracetam Oral Solution 6)

A bar chart comparing the percentage of patients between a placebo group (19.6%, N=51) and a Levetiracetam group (43.1%, N=58). The vertical axis represents the percentage of patients from 0% to 45%, with Levetiracetam showing a higher percentage than placebo.*

FDA Label Image

690afec4-figure-07 (Levetiracetam Oral Solution 7)

A bar graph comparing the percentage of patients responding to Placebo and Levetiracetam treatments. The y-axis shows percentage of patients from 0% to 100%. The Placebo group (N=84) shows 45.2% patients, while the Levetiracetam group (N=79) shows 72.2% patients. An asterisk indicates statistical significance for the Levetiracetam group.*

FDA Label Image

Label Image (Rspl17856 0685)

Levetiracetam oral solution label showing 500 mg per 5 mL concentration, marked RX only and delivers 5 mL per dose. The label includes distributor and manufacturer details, lot number placeholder, expiration date of 04/17/13, and a barcode. The product is labeled by Atlantic Biologicals Corps with NDC 17856-0685.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.